Free Deal Calculator

Calculate Bispecific Antibody Deal Values in Minutes

Get accurate, market-based licensing valuations for your bispecific programs using real deal data.

Market-Leading Accuracy

Built on analysis of 200+ bispecific deals with real-time market adjustments. Our algorithm accounts for the 35% premium bispecifics command over traditional antibodies.

Instant Professional Reports

Generate comprehensive valuation reports in under 5 minutes. Perfect for board presentations, investor discussions, and BD negotiations.

Live Market Intelligence

Access current T-cell engager deal benchmarks and trending valuation multiples. Stay ahead in the fastest-growing oncology segment.

$60M-250M

Phase 2 Upfront Range

$2.5B

Peak Deal Values

35%

Valuation Premium

200+

Deals Analyzed

How It Works

Input Your Asset Details

Enter your bispecific's stage, indication, mechanism, and competitive landscape position.

Apply Market Factors

Our algorithm weighs current market conditions, recent comparable deals, and bispecific-specific premiums.

Download Your Report

Receive detailed upfront, milestone, and royalty recommendations with supporting deal comps.

Frequently Asked Questions

How do bispecific antibody deals compare to traditional mAbs?

Bispecifics command a 35% premium on average, with Phase 2 upfronts ranging $60M-$250M versus $45M-$185M for traditional antibodies, reflecting their enhanced therapeutic potential and lower clinical risk.

What makes T-cell engagers particularly valuable?

T-cell engagers represent the fastest-growing bispecific segment, with proven clinical success driving deal values 40-50% above other bispecific formats due to their established mechanism and reduced development risk.

How current is your bispecific deal database?

Our database includes deals through Q4 2024, with weekly updates capturing new transactions, amendments, and milestone achievements that impact current market valuations.

Can the calculator handle different bispecific formats?

Yes, our algorithm differentiates between T-cell engagers, immune checkpoint inhibitor combinations, ADC-like formats, and novel mechanisms, applying appropriate valuation multiples for each.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating